Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ARCA biopharma, Inc. (NASDAQ: ABIO).

Full DD Report for ABIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ABIO)

ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions
Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) --   ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approa...
Source: GlobeNewswire
Date: November, 05 2018 08:30
Midday Gainers / Losers (10/02/2018)
Gainers:  OGEN +92% . DTEA +62% . IGC +58% . TRPX +49% . IMTE +43% . SLS +22% . SYN +20% . FTFT +19% . ATRS +19% . INO +18% . More news on: Oragenics, Inc., DAVIDs TEA, India Globalization Capital, Inc, , Stocks on the move, Top stock market news, R...
Source: SeekingAlpha
Date: October, 02 2018 12:44
Premarket Losers as of 9:05 am (10/2/2018)
ABIO -22% . More news on: ARCA biopharma, Inc., Stitch Fix, Inc., New Age Beverages Corporation, Stocks on the move, Top stock market news, , Read more ...
Source: SeekingAlpha
Date: October, 02 2018 09:09
Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average gained 0.73 percent to close at 26,651.21, while the S&P 500 Index closed 0.36 pe...
Source: ACCESSWIRE IA
Date: October, 02 2018 08:00
ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June ...
Source: GlobeNewswire
Date: August, 09 2018 16:15
Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018
CORAL GABLES, FL / ACCESSWIRE / August 3, 2018 / Both the SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology Index ETF (IBB) extended gains on Thursday afternoon. Both funds have been in an uptrend for the better part of the last 3 days to begin the month of August. For sev...
Source: ACCESSWIRE IA
Date: August, 03 2018 09:45
3 Biotech Stocks in Focus on Tuesday
CORAL GABLES, FL / ACCESSWIRE / July 31, 2018 / The Nasdaq iShares Biotechnology Index (IBB) has taken a turn toward ''greener pastures.'' The ETF rose by more than 1.2% on Tuesday as a number of biotech stocks moved higher in early morning trading. Additionally, a number of other ETF's trac...
Source: ACCESSWIRE IA
Date: July, 31 2018 12:15
FDA on board with single Phase 3 to support marketing application for ARCA Bio's Gencaro; shares up 37% premarket
Nano cap ARCA biopharma (NASDAQ: ABIO ) is up  37%  premarket on robust volume in response to its announcement that the FDA has indicated that a single Phase 3 clinical trial may be sufficient to support a U.S. marketing application for Gencaro (bucindolol hydrochloride) for the ...
Source: SeekingAlpha
Date: July, 31 2018 09:11
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indication Phase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018 Gencaro is in development as potentially the first genetically-targeted treatment for patients with atrial fibrillat...
Source: GlobeNewswire
Date: July, 31 2018 08:30
Today's Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after announcing that the FDA has approved the New Drug Application for AZEDRA . RDI Ini...
Source: ACCESSWIRE IA
Date: July, 31 2018 08:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.50970.5050.52990.50540,924
2018-12-100.510.50950.52490.503897,158
2018-12-070.50070.520.550.50283,919
2018-12-060.52050.51830.52190.502376,113
2018-12-050.51940.510.530.51119,980

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-112,7549,22729.8472Cover
2018-12-105,20026,12919.9013Cover
2018-12-0729,08266,37243.8167Short
2018-12-0615,74833,64346.8091Short
2018-12-0414,11419,99070.6053Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ABIO.


About ARCA biopharma, Inc. (NASDAQ: ABIO)

Logo for ARCA biopharma, Inc. (NASDAQ: ABIO)

Not available

 

Contact Information

 

 

Current Management

  • Michael Bristow / CEO
  • Patrick Wheeler / CEO
  • Derek Cole / IR

Current Share Structure

  • Market Cap: $7,652,876 - 05/11/2018
  • Issue and Outstanding: 13,914,320 - 03/19/2018

 


Recent Filings from (NASDAQ: ABIO)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018

 

 


Daily Technical Chart for (NASDAQ: ABIO)

Daily Technical Chart for (NASDAQ: ABIO)


Stay tuned for daily updates and more on (NASDAQ: ABIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ABIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ABIO and does not buy, sell, or trade any shares of ABIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/